L3VLUP
ProSign in

INCY · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

INCYJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • INCY
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterINCYJNJ
Q3 202016 holders, $5.4bn30 holders, $26.2bn
Q4 202015 holders, $5.1bn32 holders, $26.6bn
Q1 202113 holders, $4.6bn31 holders, $25.3bn
Q2 202113 holders, $5.3bn37 holders, $25.6bn
Q3 202115 holders, $3.9bn40 holders, $24.1bn
Q4 202121 holders, $3.6bn33 holders, $25.2bn
Q1 202217 holders, $3.5bn35 holders, $28.2bn
Q2 202218 holders, $3.6bn33 holders, $26.9bn
Q3 202217 holders, $3.0bn36 holders, $25.4bn
Q4 202221 holders, $3.5bn35 holders, $27.6bn
Q1 202321 holders, $2.8bn42 holders, $24.5bn
Q2 202323 holders, $2.7bn38 holders, $25.0bn
Q3 202323 holders, $2.5bn37 holders, $18.9bn
Q4 202319 holders, $2.5bn31 holders, $19.0bn
Q1 202420 holders, $2.1bn32 holders, $19.7bn
Q2 202418 holders, $2.1bn35 holders, $20.4bn
Q3 202416 holders, $2.2bn28 holders, $22.3bn
Q4 202414 holders, $2.0bn37 holders, $20.4bn
Q1 202513 holders, $1.9bn32 holders, $20.5bn
Q2 202515 holders, $2.6bn31 holders, $18.4bn
Q3 202513 holders, $3.0bn32 holders, $23.7bn
Q4 202513 holders, $3.5bn29 holders, $27.8bn
Q1 202613 holders, $3.4bn34 holders, $35.6bn
Q2 202615 holders, $4.4bn33 holders, $39.1bn
INCY

Incyte Corp

Holders
13
Reported value
$1.9bn
Buyers
8
Sellers
6

Breadth +2 among 95 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
JNJ

Johnson & Johnson

Holders
32
Reported value
$20.5bn
Buyers
16
Sellers
15

Breadth +1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only INCY (5)

ARK Investment Management LLC, Caxton Associates LLP, PDT Partners LLC, Point72 Asset Management LP, Voloridge Investment Management LLC

Only JNJ (24)

AllianceBernstein LP, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Element Capital Management LLC, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Quantbot Technologies LP, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Verition Fund Management LLC, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →